Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$22.45
-0.1%
$33.37
$19.16
$48.25
$1.09B1.41859,778 shs651,625 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$26.73
$26.70
$16.10
$32.14
$1.24B1.51408,809 shs433,363 shs
Varex Imaging stock logo
VREX
Varex Imaging
$10.07
$10.97
$6.76
$14.56
$423.95M0.96523,667 shs310,081 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
0.00%-1.50%-40.53%-39.87%-21.62%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-4.09%-12.13%+13.84%+31.03%
Varex Imaging stock logo
VREX
Varex Imaging
0.00%+4.24%-19.63%-24.34%+33.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$22.45
-0.1%
$33.37
$19.16
$48.25
$1.09B1.41859,778 shs651,625 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$26.73
$26.70
$16.10
$32.14
$1.24B1.51408,809 shs433,363 shs
Varex Imaging stock logo
VREX
Varex Imaging
$10.07
$10.97
$6.76
$14.56
$423.95M0.96523,667 shs310,081 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
0.00%-1.50%-40.53%-39.87%-21.62%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-4.09%-12.13%+13.84%+31.03%
Varex Imaging stock logo
VREX
Varex Imaging
0.00%+4.24%-19.63%-24.34%+33.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.88
Moderate Buy$47.83113.09% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.91
Moderate Buy$43.1361.34% Upside
Varex Imaging stock logo
VREX
Varex Imaging
2.60
Moderate Buy$16.1760.54% Upside

Current Analyst Ratings Breakdown

Latest AVBP, AORT, and VREX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated RatingOverweight
5/20/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingHold (C-)
5/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Lower Price TargetBuy$45.00 ➝ $43.00
5/8/2026
Artivion, Inc. stock logo
AORT
Artivion
Lower Price TargetMarket Outperform$53.00 ➝ $48.00
5/8/2026
Artivion, Inc. stock logo
AORT
Artivion
Lower Price TargetBuy$58.00 ➝ $44.00
5/4/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
UpgradeStrong-Buy
4/24/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Boost Price TargetBuy$33.00 ➝ $45.00
4/20/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated RatingSell (D-)
4/20/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingBuy
4/13/2026
Varex Imaging stock logo
VREX
Varex Imaging
UpgradeHoldStrong-Buy
4/10/2026
Artivion, Inc. stock logo
AORT
Artivion
UpgradeNeutralBuy$42.00
(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$441.33M2.47$1.10 per share20.38$9.28 per share2.42
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$6.96 per shareN/A
Varex Imaging stock logo
VREX
Varex Imaging
$844.60M0.50$3.89 per share2.59$11.59 per share0.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
$9.77M$0.2493.5329.93N/A2.55%7.15%3.63%8/6/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)
Varex Imaging stock logo
VREX
Varex Imaging
-$70.30M-$2.00N/A9.15N/A-9.64%8.19%3.63%8/6/2026 (Estimated)

Latest AVBP, AORT, and VREX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.88-$0.96-$0.08-$0.96N/AN/A
5/7/2026Q2 2026
Varex Imaging stock logo
VREX
Varex Imaging
$0.22$0.21-$0.01-$0.19$216.92 million$216.00 million
3/5/2026Q4 2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.87-$0.78+$0.09-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Varex Imaging stock logo
VREX
Varex Imaging
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.48
3.86
2.80
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
13.95
13.95
Varex Imaging stock logo
VREX
Varex Imaging
0.67
3.20
1.43

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Varex Imaging stock logo
VREX
Varex Imaging
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
6.30%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Varex Imaging stock logo
VREX
Varex Imaging
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,80048.54 million45.49 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4046.58 million42.58 millionN/A
Varex Imaging stock logo
VREX
Varex Imaging
2,40042.10 million40.16 millionOptionable

Recent News About These Companies

Varex Imaging (VREX) Receives a Buy from Oppenheimer
Analysts Set Varex Imaging (NASDAQ:VREX) Price Target at $16.17
Varex Imaging Q2 Earnings Call Highlights
Varex Imaging (VREX) Q2 2026 Earnings Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$22.45 -0.01 (-0.06%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$22.46 +0.02 (+0.08%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$26.73 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$26.73 0.00 (0.00%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Varex Imaging stock logo

Varex Imaging NASDAQ:VREX

$10.07 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$10.06 -0.02 (-0.15%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.